EMA Management Board Meeting Highlights: March 2026 on Clinical Trials
Decision brief
Answer first · skim in under a minute
The EMA Management Board's March 2026 meeting focused on critical updates regarding clinical trials. This article outlines key takeaways and their implications for the pharmaceutical sector.
The EMA Management Board’s 12 March 2026 meeting focused on clinical trial competitiveness: Biotech Act proposals, CTIS modernisation, ACT EU delivery, and data-protection updates for CTIS. Primary minutes and board highlights now detail what sponsors should expect in 2026 workflows.
Contents11 sections
Key Takeaways
- Board meeting held 12 March 2026; highlights published 13 March 2026 on ema.europa.eu.
- DG SANTE updated members on Biotech Act clinical-trial provisions and FAST-EU progress (seven applications under assessment; third call opening 23 March).
- ACT EU planned April 2026 publication of first KPIs on trial attractiveness and speed; CTIS safety module slated for June 2026.
- Board endorsed an updated CTIS Joint Controllership Arrangement on 12 March 2026 after revised transparency rules.
What clinical-trial topics did the Board cover?
EMA’s March 2026 Management Board highlights state the Board was updated on Biotech Act proposals on clinical trials and on the Commission’s Clinical Research Investment Plan alongside ACT EU.
Adopted minutes (EMA/MB/57340/2026) record DG SANTE’s legislative update and DG RTD’s Clinical Research Investment Plan presentation for multi-country trials.
What is changing for CTIS in 2026?
Board highlights say further CTIS modernisation is planned in 2026, including a new CTIS safety module in June, with improvement plans also reflecting Biotech Act implications. Minutes note a revised CTIS development plan would be needed within one month of Biotech Act entry into force, with additional FTEs and €15 million foreseen from 2028.
What did ACT EU report?
Highlights note ACT EU’s first 2026 Multi Stakeholder Platform Advisory Group meeting on 20 March, a call for a new stakeholder co-chair, multiannual workplan revision, and April publication of first KPIs on clinical trial attractiveness and speed.
- Meeting date: 12 March 2026
- CTIS safety module: June 2026
- FAST-EU: 7 applications under assessment
Why does the CTIS JCA update matter?
EMA’s CTIS JCA Q&A (version 1.1, 12 March 2026) states the Management Board endorsed an updated Joint Controllership Arrangement that day following revised CTIS transparency rules, affecting how controllers handle personal data in the system.
What remains unsettled?
Biotech Act text was still moving through Council and Parliament at the meeting. Resource timing for CTIS rebuild work before formal adoption was flagged as an open Agency issue in the minutes—sponsors should not assume final architecture dates until legislation is adopted.
How should sponsors respond?
Monitor ACT EU KPI releases, prepare for the June CTIS safety module, and map protocol submissions against FAST-EU and Biotech Act simplification goals. Use ema.europa.eu board documents as the source of truth for governance claims.
What does FAST-EU signal for multi-country trials?
Minutes note FAST-EU already had seven clinical trial applications under assessment with a third call opening on 23 March 2026. That pipeline is a concrete leading indicator of Commission ambition to speed multinational starts inside the existing CTIS framework.
Sponsors planning 2026–2027 EU programmes should map protocol complexity against ACT EU KPI definitions once the April attractiveness and speed metrics publish, and budget for CTIS safety-module training ahead of the June rollout cited in board highlights.
Related NovaPharma coverage
Frequently Asked Questions
When was the March 2026 EMA Management Board meeting?
The Management Board met on 12 March 2026; EMA published meeting highlights on 13 March 2026.
What CTIS change is planned for mid-2026?
Board highlights state a new CTIS safety module is planned for rollout in June 2026.
Did the Board update CTIS data-protection arrangements?
Yes. On 12 March 2026 the Board endorsed an updated CTIS Joint Controllership Arrangement after revised transparency rules.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
